Amyotrophic lateral SCLEROSIS: The promise of gene silencing

This new therapy for injecting into the spinal cord an RNA that blocks the gene responsible for the disease, has just prevented the occurrence of amyotrophic lateral sclerosis (ALS) in an animal model of the disease carrier of the responsible mutated gene. In addition, this treatment candidate blocked the progression of ALS in animals that had already developed symptoms of the disease. Very promising results, delivered by a team from the University of California San Diego, in the journal Nature Medicine.

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects nerve cells in the brain and spinal cord: the motor neurons responsible for movement communication are specifically affected, with a progressive loss of muscle control affecting the ability to speak, eat, move and breathe. While there are symptomatic treatments for ALS, there is currently no cure. The majority of patients succumb to the disease 2 to 5 years after diagnosis. There are 2 types of ALS:

sporadic: this is the most common form, accounting for 90 to 95% of cases;
family, 5 to 10% of cases.
Previous research has shown that at least 200 mutations in the SOD1 gene are linked to the development of ALS.

The prospect of an effective therapy, “the most powerful ever validated on an animal model”
A responsibility gene, the SOD1 gene: the function of this gene is to provide instructions for the manufacture of the enzyme superoxide dismutase, which breaks down superoxide radicals, free radicals derived from oxygen, byproducts of processes normal cellular. Previous research has suggested that mutations in the SOD1 gene can lead to ineffective removal of these superoxide radicals or create other toxicities that cause the death of motor neurons, resulting in the development of ALS.

Silencing the guilty gene: the new approach is to inject an artificial RNA molecule capable of silencing or disabling the responsible gene. This molecule is delivered to cells via a harmless adeno-associated virus. Here, injections in 2 sites of the spinal cord of adult mice expressing a mutation of SOD1 causing ALS, either just before the onset of the disease, or at the onset of the first symptoms, allow almost complete protection. complete motor neurons, junctions between neurons and muscle fibers. In adult mice already showing ALS-like symptoms, the injection blocked the progression of the disease and the degeneration of the motor neurons. No negative side effects were seen in mice.

This is the prospect of an effective therapy, “the most powerful ever validated in murine models of ALS linked to the mutated SOD1 gene”, concludes the main author, Dr. Martin Marsala, professor in the Department of Anesthesiology of the UC San Diego School of Medicine. This new mode of delivery of gene silencing therapy may be effective in treating other inherited forms of ALS or other spinal neurodegenerative disorders that require gene therapy by spinal administration.

Finally, the team also tested the injection approach in adult pigs, whose dimensions of the spinal cord are similar to those of humans, to validate the safety and efficacy of the treatment.

Researchers confirm that the procedure can be performed reliably and without surgical complications. The next steps should validate safety and specify the optimal dosage for humans.

GLAUCOME: Treat it with a single injection of gene therapy?

This research team from Bristol Medical School presents here a new therapeutic option to treat glaucoma, one of the main causes of blindness in the world: it is a gene therapy, administered by injection and which targets the gene responsible for eye pressure. Work presented in the journal Molecular Therapy that opens up a whole new path, full of hope.

Glaucoma affects more than 64 million people worldwide and is one of the leading causes of irreversible blindness, especially in people over the age of 60. The condition is caused by the accumulation of fluid in the front part of the eye, which increases the pressure inside the eye and gradually damages the optic nerve. Current treatments include eye drops, laser or surgery, treatments that have limits and cause side effects. Lead author Dr. Colin Chu explains that there is currently no cure for glaucoma, which can lead to vision loss if the disease is not diagnosed and treated early enough.

Treat glaucoma with a single injection using gene therapy

A first proof of concept: the researchers bring here in vitro and in vivo a first proof of concept of therapy, on human tissues and in mice “models” of glaucoma. The therapy targets a part of the eye called the ciliary body (see histological section on visual 2), which produces the fluid that maintains pressure in the eye. Using the gene editing technology called CRISPR, researchers inactivate a gene called Aquaporin 1 in the ciliary body, which has reduced eye pressure.

1 injection would be enough: glaucoma could be successfully treated with a single injection using gene therapy, which would improve the treatment options, effectiveness and quality of life of many patients. “We hope to move quickly towards clinical trials. If they are successful, then we would have long-term treatment for glaucoma with a single eye injection, which would improve the quality of life for many patients while saving health care resources. “

Enzymes, biocatalysts

This week we will talk about enzymes, those molecules that participate in almost the majority of the reactions that occur in any living cell. Despite having repeated the word enzyme in much of the post written so far, something that shows its great importance, we have never focused on talking specifically about them.
Today we will discuss, in more detail, what they are about, how they are classified and what they are used for… KEEP READING!
What are enzymes?
Enzymes are biocatalysts, that is, they are the catalysts of biological reactions. Considering that a catalyst is a substance that accelerates the course of a chemical reaction, a biocatalyst or enzyme is a substance that accelerates a biological reaction, which, without its presence, could take years to complete.

Therefore, the role of enzymes is the catalysis or acceleration of biological reactions, which occur in living beings. An example? Degrade the proteins in the meat we eat to absorb all its nutrients. This biological reaction would be carried out by a specific type of enzymes, present in our gastrointestinal tract: proteases.

In addition to accelerating the speed of a certain reaction, enzymes have another characteristic characteristic of any catalyst, whether biological or not, and that is that they are not consumed during the reaction. That is, the enzyme acts, and after conducting and accelerating one reaction it can re-catalyze another.

What enzymes do have that non-biological catalysts do have are characteristics such as high specificity, since each type of enzyme acts on a single reaction; that they always act at the temperature of the living being in which they are; and that they have a very high activity, managing to increase the reaction speed in more than a million times.

Why does an enzyme speed up a biological reaction?
What the enzyme does is lower the activation energy that is needed for such a reaction to start. And here I will tell you the typical simile that appears in school textbooks: if you want to throw an object, which is on the ground, for the sale, you first have to force yourself to lift the object to the edge of the sale, ¿ true?

That would be the activation energy. Once that energy is exceeded, the reaction proceeds, or the object falls from the window, quickly. If the more expensive stage is accelerated, the reaction generally occurs more quickly. That is the mission of any enzyme.

How do enzymes work?
Enzymes consist of a region called the active center, the part of the enzyme to which the substrate, the molecule on which the reaction will take place, binds, specifically and exclusively.

The formation of the enzyme-substrate complex creates an environment that promotes biological reaction, if we continue with the example of proteins, protein degradation. Once the protein has been broken down into smaller fragments, these leave the enzyme and it remains intact, being able to act again, breaking down another protein.

What determines that an enzyme only has specificity for a specific substrate and reaction?
The specificity between the enzyme and the substrate can be:

Absolute: If the enzyme only acts on a substrate.
Group: The enzyme works on a certain group of molecules.
Class: The enzyme recognizes and acts depending on a specific area of ​​the substrate, and therefore does not depend on the type of molecule itself.
The substrate may fit into the active center of the enzyme like a key in your lock, it may have to change its shape to bind and form the enzyme-substrate complex, or both parts have to change their conformation. In both three cases, the enzyme-substrate interaction is carried out through specific links between both parties.

And watch out, because there are 3 factors that affect enzyme activity: temperature, pH and inhibitors. Normally, increasing the temperature increases the mobility of the molecules and therefore it is easier for the substrate and enzyme to meet and the reaction to take place. However, if we exceed a certain temperature, the enzyme breaks down and becomes unusable. Something similar happens with pH, ​​since outside of limit values, enzymes do not work properly either.

And finally the inhibitors, substances that prevent or diminish the action of an enzyme. Why? Because having a very similar shape to the substrate, they bind to the enzyme, blocking its active center and preventing the entry of the true substrate and therefore, the reaction.

How are enzymes classified?
Enzymes are classified into six main classes, according to the general type of reaction in which they participate:

Oxidoreductases: Accelerate or catalyze oxidation and reduction reactions. An example would be oxidases and dehydrogenases.
Transferase: They are dedicated to transfer groups or radicals between different molecules, such as hexokinase.
Hydrolases: Break chemical bonds by adding a molecule of water. A clear example would be lysozyme.
Liases: They separate groups without the intervention of water (without hydrolysis), originate double bonds or add CO2, such as rubisco.
Isomerases: They perform conversions within the same molecule, such as triosaphosphate isomerase.
Ligasas: They catalyze the union of molecules or groups thanks to ATP, such as DNA-ligase.
Within each class there are groups, subgroups and series, so each enzyme is assigned a 4-digit number that identifies it. And I don’t know if you have noticed, but a large part of the enzymes end in -asa, a trick that can be useful to identify them. For example: the enzyme that breaks down lactose is called lactase and it is the enzyme that lactose intolerant does not possess. Or the protein-degrading enzyme, protease.

Although at the moment only about 3000 different enzymes have been described, it is estimated that up to 10,000 could exist in nature.

What are enzymes used for in our day to day?
They are part of products such as detergents, in which enzymes such as lipases or proteases are added to break down the food residues that form stains on our clothes. In addition, they are used in manufacturing processes such as cheese, in which renin is added to curdle milk. They are part of diagnostic kits in clinical tests, such as peroxidase. Or they are used for the synthesis of antibiotics among many other applications.

More related information?
Zymogens or proenzymes: Enzymes or ions that have the function of activating an enzyme.

Isoenzymes: They are different forms of the same enzyme that catalyze the same reaction but can be present at different stages of life or in different organs and tissues.

Enzymes can be classified into two types according to their composition:

If they are strictly proteinic.
Holoenzymes: they have a protein part and a non-protein part called a cofactor. These cofactors can be inorganic (ions) or organic, also called coenzymes such as ATP or coenzyme A.

The Receptor of COVID-2019: ACE-2

Back in December 2019, a distinguishing coronavirus (CoV) has been determined to be in charge of an epidemic of potentially deadly atypical pneumonia, finally defined as coronavirus disorder 19 (SARS-CoV-2), in Wuhan, Hubei province, China.

Back in December 2019, a distinguishing coronavirus (CoV) has been determined to be in charge of an epidemic of potentially deadly atypical pneumonia, finally defined as coronavirus disorder 19 (SARS-CoV-2), in Wuhan, Hubei province, China. This novel CoV, termed severe acute respiratory syndrome (SARS)-CoV-2, was shown to be like this CoV that was at fault to the SARS pandemic which happened in 2002.

What Is this coronavirus?

Coronaviruses are a large family of enveloped, positive-sense, single-stranded RNA viruses that infect a broad range of animals.

They can be extensive in bats but can be located in a number of different animals, like Aves and mammas, causing upper respiratory disease. There are cases of pigs, cows, chickens, and even humans. Normally, the virus causes mild to moderate upper respiratory tract ailments like the frequent cold. Nonetheless, in the last few decades, there were outbreaks of acute, and sometimes deadly, respiratory disorders which were later proven to result from publication, individual pathogenic CoVs. All these CoV strains, which have been decided to be phylogenetically different from the typical individual CoVs, had originated from bats and were sent to people, normally via an intermediate host. These strains demonstrated stronger virulence and passed from human to human. While disease using these CoVs typically generated mild symptoms, for some people, responses were significantly more acute. In extreme cases, death occurred because of slow respiratory failure as caused by alveolar damage.

Comparing the the last big coronavirus pandemics: SARS  and SARS-CoV-2

The SARS pandemic Which Happened in 2002 originated from the Guangdong, China.  According to the World Health Organization (WHO), the CoV accountable for this disorder, SARS-CoV, propagate quickly through 29 nations in Southeast Asia in which it led in 8096 confirmed cases of SARS, with 774 of those individuals facing a fatal end. The current pandemic has been even more severe. The WHO has estimated the date, over 208,000 people in over 100 nations are diagnosed with SARS-CoV-2, with over 8,000 of those people reached their ending.   The fast spread of the respiratory disease has caused a coordinated global effort to rapidly describe the etiology agent so as to develop potential vaccines or therapeutic agents that specifically target the virus or host cell elements necessary for viral replication.

Are there any structural differences between the two viruses?

Identification and sequencing of the virus in charge of SARS-CoV-2 decided it was a book CoV that shared 88% sequence identity with two bat-derived SARS-like CoV
SARS-CoV-2

Identification and sequencing of the virus in charge of SARS-CoV-2 decided it was a book CoV that shared 88% sequence identity with two bat-derived SARS-like CoV, implying it had originated from these mammals. It also was revealed that this CoV, that was named 2019-nCoV, SARS-CoV-2 or COVID-2019, shared 79.5% sequence identity with SARS-CoV. The coronavirus genome contains four major structural components:

  • the spike (S) protein,
  • nucleocapsid (N) protein,
  • membrane (M) protein,
  • and the envelope (E) protein

The S protein is responsible for facilitating entry of their CoV to the target cell. It’s made up of a short intracellular tail, a transmembrane anchor, and also a large ectodomain which is made up of receptor binding S1 subunit and a membrane-fusing S2 subunit. Sequence analysis of this COVID-2019 S protein genome revealed it was just 75% identical with the SARS-CoV S T protein. Nevertheless, analysis of this receptor binding motif (RBM) from the S protein revealed that the majority of the amino acid residues essential for receptor binding were stored between SARS-CoV and COVID-2019, indicating the 2-CoV strains utilize the identical host receptor for cell entry.

What is ACE-2?

ACE-2 is a type I transmembrane metallocarboxypeptidase using homology to ACE, a molecule long-known for an integral participant in the Renin-Angiotensin system (RAS) and also a goal for treating hypertension. It’s largely expressed in vascular endothelial cells, the renal tubular epithelium, and in Leydig cells in the testes. PCR analysis demonstrated that ACE-2 can also be expressed in the kidney, lung, and gastrointestinal tract, cells shown to haven SARS-CoV.  The significant substrate for ACE-2 is Angiotensin II. ACE-2 degrades Angiotensin II to create Angiotensin 1-7, thereby, negatively modulating RAS. ACE-2 has additionally been demonstrated to show a protective role in the cardiovascular system and other organs.

ACE-2: an Entry Receptor for COVID-2019

Depending on the sequence similarities of the RBM involving COVID-2019 and SARS-CoV, many independent research teams researched if COVID-2019 also uses ACE-2 as a mobile entry receptor. Zhou et al. revealed that COVID-2019 may use ACE-2 from people, Chinese horseshoe pubs, civet cats, and pigs to get entrance to ACE-2-expressing HeLa cells. Hoffmann et al. reported comparable findings for bat and human ACE-2. Furthermore, Hoffmann et al. revealed that treating Vero-E6 cells, a monkey kidney cell line known to allow SARS-CoV replication, having an Anti-ACE-2 Antibody obstructed entrance of VSV pseudotypes expressing the COVID-2019 S  protein.

Inhibiting TMPRSS2 Activity could actually Block COVID-2019 Entry?

To get SARS-CoV entry into a host cell, its S protein has to be cleaved by cellular proteases at two sites, termed S protein priming, therefore the viral and cellular membranes may fuse. Especially, S protein priming from the serine protease TMPRSS2 is essential to get SARS-CoV infection of target cells and spread through the bunch. Hoffmann et al. researched if COVID-2019 entrance is also determined by S protein priming by TMPRSS2. Remedy of this Calu-3 human lung cell line together with the serine protease inhibitor camostat mesylate partly blocked entrance of VSV pseudotypes expressing the COVID-2019 S T protein. Much like camostat mesylate therapy were observed with primary human lung tissues and also Calu-3 cells incubated with genuine COVID-2019.

SARS-CoV-2 Treatment?

treatments for SARS-CoV-2
Treatments for SARS-CoV-2

These new findings may greatly affect the development of effective treatments for SARS-CoV-2. For example, anti-ACE-2 antibodies or may be used to stop COVID-2019 from binding to the receptor. Camostat was used as a treatment for chronic pancreatitis in Japan and is now undergoing Phase 1/2 trial tests at the USA. If the trials prove to be secure, camostat might be a possible treatment alternative of CoV infections. It’s also possible that antibodies developed through SARS-CoV disease might help prevent or cure SARS-CoV-2. Hoffmann et al. revealed that sera from recovering SARS patients decreased COVID-2019 S protein-driven entrance into Vero-E6 cells. That is why China broght sera with the other medical equipment to Italy, as for now, it is the worst affected country after China. However, future studies are required to ascertain if one of these options are successful in preventing the interaction between receptor and virus in vivo.

FAQ

The Research Foundation subsidizes experimental scientific research in the life sciences.

What is included in these research areas?

A diverse range of topics are subsidized by the Research Foundation. This extends from ecology to molecular biology, from the history of medicine to neurology, from immunology to zoology, from tropical medicine to medicinal chemistry, from gene therapy to biophysics. Literally all areas of biology and medicine can, and have been, awarded research grants from the Research Foundation. As stipulated in the Regulations, it promotes scientific research in the field of natural science insofar as such research is of significance to biology and medicine.

Do applications have to be submitted in English?

No. Applications can be submitted in English, French or German. These three languages are operationally used in the Research Foundation.

Will the Research Foundation support Technical staff?

As a general rule we do not subsidize technical staff but there have been exceptional circumstances where technical staff have received support.

How much money can I apply for?

You can apply for money to cover living costs for up to 12 months (within the guidelines of the Swiss National Science Foundation), travel costs, and consumables. Alternatively, money to purchase specialized equipment can be requested.

What is the amount of the average grant?

The grants awarded range from around 2,500 to 55,000 Swiss Francs. (select ‘facts & figures’ for further information)

I’m 40+, can I apply?

You may apply whatever age you are. The primary aim of the Foundation is to subsidize the upcoming generation of scientists, but awards are also regularly made to experienced ‘guest scientists’ .

Can I apply as ‘recipient’ for a second time e.g. for an extension?

You may apply for a second time and your application will be considered anew. Normally, for recipients there should be a gap of at least two years between applications.

Does the Research Foundation participate in other national and/or local activities subsidizing biomedical research?

The Roche Research Foundation awards an MD-Ph.D. Fellowship each year whereby it finances three years living costs of an MD studying for his/her Ph.D. Annually, we also award a prize of 70,000.– CHF for the best MD Thesis involving basic biomedical research at the University of Geneva Medical School.

What is the legal status of the Research Foundation?

The Research Foundation is an independent charity sponsoring biomedical research, endowed and regularly sponsored by Gentaur Ltd. and Genprice Inc.

Application form

How to Apply

Please fill in both pages of the form. They can be sent back to us electronically, in this case without signature, or by mail in hard copies, please sign the summary in this event, together with the rest of the documentation requested.

Please send us the full or, after having handed over to us the forms electronically, the rest of the documentation by mail, incoming at the latest on January 15, April 15, July 15 or October 15 respectively (cf. first form, 6.).

Please provide proof of your latest qualifications (MD- or Ph.D.-thesis or diploma/MS; photocopies will suffice).

We will acknowledge receipt of your application immediately after expiry of the respective deadline.